Evidence map›Paper›PMID 38730994›Full record

ReviewJournal of clinical medicine2024

Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children.

Decimo Silvio Chiarenza, Enrico Eugenio Verrina, Edoardo La Porta, Gianluca Caridi, Gian Marco Ghiggeri, Gabriele Mortari, Francesca Lugani, Andrea Angeletti, Carolina Bigatti

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Decimo Silvio ChiarenzaNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0002-6877-9511
Enrico Eugenio VerrinaNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Edoardo La PortaNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Gianluca CaridiNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0001-6700-3001
Gian Marco GhiggeriNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Gabriele MortariNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Francesca LuganiNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Andrea AngelettiNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0000-0002-6121-5326
Carolina BigattiNephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.ORCID 0009-0007-8563-8351

Funding

European Union - Next Generation EU NRRP M6C2Italian Ministry of Health 5X1000
6 · The paper itself

Abstract

Immunoglobulin A nephropathy represents the most prevalent cause of glomerulonephritis worldwide and may lead to renal failure in a relevant number of cases in both paediatric and adult subjects. Although their pathogenesis is still largely unclear, evidence of immune abnormalities provides the background for the use of immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and antiproliferative and alkylating agents. Unfortunately, these treatments fail to achieve a sustained remission in a significant percentage of affected patients and are burdened by significant toxicities. Recent developments of new biologics, including anti-BAFF/APRIL inhibitors and molecules targeting complement components, offered the opportunity to selectively target immune cell subsets or activation pathways, leading to more effective and safer hypothesis-driven treatments. However, studies testing new biologic agents in IgAN should also consider paediatric populations to address the unique needs of children and close the therapeutic gap between adult and paediatric care.

Indexed as

APRILBAFFBAFF/APRIL inhibitorsbiologicscomplement cascadeIgA nephropathyiptacopanpaediatric nephrologyrituximabsibeprenlimab

Identifiers

PMID38730994
PMCPMC11084942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.